Ken Griffin Incyte Corp Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $2.55 Million - $3.05 Million	44,400 Added 63.43%	114,400 $7.56 Million
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $5,118 - $6,375	-100 Reduced 0.14%	70,000 $4.24 Million
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $1.16 Million - $1.37 Million	-20,600 Reduced 22.71%	70,100 $3.99 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $631,136 - $776,699	12,100 Added 15.39%	90,700 $5.7 Million
Q3 2023 Nov 14, 2023	SELL	$57.77 - $65.93 $1.02 Million - $1.17 Million	-17,700 Reduced 18.38%	78,600 $4.54 Million
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $3.5 Million - $4.34 Million	57,500 Added 148.2%	96,300 $5.99 Million
Q1 2023 May 15, 2023	SELL	$70.23 - $86.01 $8.44 Million - $10.3 Million	-120,200 Reduced 75.6%	38,800 $2.8 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $7.07 Million - $8.86 Million	-105,300 Reduced 39.84%	159,000 $12.8 Million
Q3 2022 Nov 14, 2022	BUY	$66.18 - $82.86 $5.98 Million - $7.48 Million	90,300 Added 51.9%	264,300 $17.6 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.